WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205792

CAS#: 1184173-73-6 (free base)

Description: MK-8353, also known as SCH900353, is a potent and orally active ERK1/2 inhibitor and anticancer drug candidate currently being developed by Schering-Plough. MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models.

Chemical Structure

CAS# 1184173-73-6 (free base)

Theoretical Analysis

MedKoo Cat#: 205792
Name: MK-8353
CAS#: 1184173-73-6 (free base)
Chemical Formula: C37H41N9O3S
Exact Mass: 691.3053
Molecular Weight: 691.855
Elemental Analysis: C, 64.23; H, 5.97; N, 18.22; O, 6.94; S, 4.63

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-03-05. Prices are subject to change without notice.

MK-8353 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Related CAS #: 1184173-73-6 (free base)   1951448-73-9 (HCl)   1951448-74-0 (HCl hydrate)   1951428-60-6 (hydrate)   1951428-61-7 (x HCl)    

Synonym: SCH900353; SCH-900353; SCH 900353; MK-8353; MK 8353; MK8353.

IUPAC/Chemical Name: (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide


InChi Code: InChI=1S/C37H41N9O3S/c1-24(2)49-32-12-9-28(20-38-32)34-30-19-29(10-11-31(30)41-42-34)40-36(48)37(50-4)15-18-45(22-37)21-33(47)46-16-13-26(14-17-46)25-5-7-27(8-6-25)35-39-23-44(3)43-35/h5-13,19-20,23-24H,14-18,21-22H2,1-4H3,(H,40,48)(H,41,42)/t37-/m0/s1

SMILES Code: O=C(CN1CC[C@@](SC)(C(NC2=CC=C(NN=C3C4=CC=C(OC(C)C)N=C4)C3=C2)=O)C1)N5CCC(C6=CC=C(C7=NN(C)C=N7)C=C6)=CC5

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 691.855 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

 1: Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC,
Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar
AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P,
Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty
KT. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients
with advanced solid tumors. JCI Insight. 2018 Feb 22;3(4). pii: 92352. doi:
10.1172/jci.insight.92352. [Epub ahead of print] PubMed PMID: 29467321.

Additional Information

Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors may overcome the limitations of MAPK inhibitor blockade.